Skip to content
Review Open access

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer

Aug 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 101 references
Medicine

TL;DR

The structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment are reviewed.

Abstract

The poliovirus receptor (CD155) is an emerging immune checkpoint molecule involved in the suppression of anti-tumor immunity. In ovarian cancer, CD155 is frequently overexpressed and interacts with receptors such as TIGIT, CD96, and CD226 to modulate the activity of T cells, NK cells, and dendritic cells. These interactions contribute to immune cell exhaustion, regulatory T cell expansion, and impaired cytotoxic responses, facilitating tumor immune evasion. Recent studies have revealed that CD155 expression is influenced by tumor metabolism, autophagy, and cytokine signaling. Therapeutic strategies targeting the CD155 axis—through monoclonal antibodies, bispecific constructs, or engineered T/NK cells—are being actively explored and show promise in enhancing anti-tumor responses, particularly when combined with existing checkpoint inhibitors. This review provides a comprehensive overview of the structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment. We discuss the signaling mechanisms of the TIGIT/CD96/CD226 axis, its impact on diverse immune cell populations, and the current landscape of therapeutic strategies targeting this pathway. Finally, we evaluate the potential of CD155 and its receptors as predictive biomarkers and therapeutic targets to overcome immune resistance and improve outcomes in ovarian cancer.

Read PDF

Similar papers

Review Open access Aug 2026

The CD155-TIGIT Signaling Axis in NK Cell Immune Evasion in Tumors: Mechanisms, Synergy with TGF-β, and Combined Intervention Strategies

This review systematically integrates and finds that TGF-β not only directly suppresses NK cell function but also upregulates cluster of differentiation 155 (CD155) expression on tumor cells through both classical and non-classical pathways, able to amplify TIGIT-mediated negative signaling.

Shu-Yun Liu · 0 citations
Open access Sep 2026

Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia

This study identified TIGIT KO as a potent enhancer of AdCAR-T-cell function and supports ICR gene disruption as a promising approach to improve therapeutic efficacy while reducing the systemic toxicities commonly associated with ICI therapy.

Anna-Sophia Mast, D. Atar, Lara Ruoff et al. · 0 citations
Review Open access Aug 2026

Targeting immune checkpoint B7-H6 in cancer immunotherapy

Current findings position B7-H6 as a promising immuno-oncologic target at the intersection of immune surveillance, immune escape, and malignant progression, warranting continued investigation as a next-generation therapeutic axis in cancer immunotherapy.

Ziyi Yang, Qi Zhao · 0 citations
Review Open access Sep 2026

Dysfunction of CD58 in tumor immune evasion: from mechanistic regulation to therapeutic resistance

CD58, the primary ligand of the co-stimulatory receptor CD2, plays a crucial role in the formation of the immunological synapse (IS) and the initiation of antitumor immunity involving T cells and natural killer (NK) cells. Aberrant CD58 expression, resulting from genomic inactivation, epigenetic silencing, transcript...

Peng-Fei Guo, Ming Yi, Yu-Jie Gan et al. · 0 citations
Open access Aug 2026

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1

In vitro data revealed that a bispecific antibody simultaneously engaging PD-L1 and CD38 exhibited markedly enhanced antitumor efficacy—even under conditions of reduced CD38 surface expression on MM cells.

Chaofan Wang, Wanting Wang, Mo-Ran Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.